Serum levels of cytokines in systemic lupus erythematosus: Association study in a Chinese population

Zeitschrift fur Rheumatologie

Volumn 73, Issue 3, 2014, Pages 277-280

  Zhang, M ^a   Xu, W D ^a   Zhu, Y ^a   Wen, P F ^a   Leng, R X ^a   Pan, H F ^a   Ye, D Q ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Autoantibodies; Genetic polymorphism; Interleukins; Lupus nephritis; Synovial membrane

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 19; INTERLEUKIN 24; INTERLEUKIN 26; INTERLEUKIN 31; INTERLEUKIN 32; INTERLEUKIN 36; INTERLEUKIN 6; UNCLASSIFIED DRUG; AUTACOID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CHINA; LUPUS ERYTHEMATOSUS, SYSTEMIC; PREVALENCE; REPRODUCIBILITY; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; BIOMARKERS; CHINA; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREVALENCE; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84898815253     PISSN: 03401855     EISSN: 14351250     Source Type: Journal    
DOI: 10.1007/s00393-013-1274-y     Document Type: Article

References (35)

1. Chun HY, Chung JW, Kim HA et al (2007) Cytokine IL-6 and IL-10 as biomarkers in systemic lupus erythematosus. J Clin Immunol 27(5):461-466
2. Sabry A, Sheashaa H, El-Husseini A et al (2006) Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity. Cytokine 35(3-4):148-153
3. Illei GG, Shirota Y, Yarboro CH et al (2010) Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 62(2):542-552
4. Zhu LJ, Yang X, Yu XQ (2010) Anti-TNF-alpha therapies in systemic lupus erythematosus. J Biomed Biotechnol 2010:465898
5. Aringer M, Graninger WB, Steiner G, Smolen JS (2004) Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 50(10):3161-3169
6. Aringer M, Houssiau F, Gordon C et al (2009) Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 48(11):1451-1454
7. Duarte AL, Dantas AT, Ataíde Mariz H de et al (2013) Decreased serum interleukin 27 in Brazilian systemic lupus erythematosus patients. Mol Biol Rep 40(8):4889-4892
8. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
9. Qiu F, Song L, Yang N, Li X (2013) Glucocorticoid downregulates expression of IL-12 family cytokines in systemic lupus erythematosus patients. Lupus 22(10):1011-1016
10. Cepika AM, Soldo Jureša D, Morović Vergles J et al (2012) Decrease in circulating DNA, IL-10 and BAFF levels in newly-diagnosed SLE patients after corticosteroid and chloroquine treatment. Cell Immunol 276(1-2):196-203
11. Pan HF, Leng RX, Feng CC et al (2013) Expression profiles of Th17 pathway related genes in human systemic lupus erythematosus. Mol Biol Rep 40(1):391-399
12. Alanärä T, Karstila K, Moilanen T et al (2010) Expression of IL-10 family cytokines in rheumatoid arthritis: elevated levels of IL-19 in the joints. Scand J Rheumatol 39(2):118-126
13. Corvaisier M, Delneste Y, Jeanvoine H et al (2012) IL-26 is overexpressed in rheumatoid arthritis and induces proinflammatory cytokine production and Th17 cell generation. PLoS Biol 10(9):e100139
14. Sakurai N, Kuroiwa T, Ikeuchi H et al (2008) Expression of IL-19 and its receptors in RA: potential role for synovial hyperplasia formation. Rheumatology (Oxford) 47(6):815-820
15. Wang F, Smith N, Maier L et al (2012) Etanercept suppresses regenerative hyperplasia in psoriasis by acutely downregulating epidermal expression of interleukin (IL)-19, IL-20 and IL-24. Br J Dermatol 167(1):92-102
16. Ciccia F, Rizzo A, Accardo-Palumbo A et al (2012) Increased expression of interleukin-32 in the inflamed ileum of ankylosing spondylitis patients. Rheumatology (Oxford) 51(11):1966-1972
17. Gui M, Zhang H, Zhong K et al (2013) Clinical significance of interleukin-32 expression in patients with rheumatoid arthritis. Asian Pac J Allergy Immunol 31(1):73-78
18. Frey S, Derer A, Messbacher ME et al (2013) The novel cytokine interleukin-36α is expressed in psoriatic and rheumatoid arthritis synovium. Ann Rheum Dis 72(9):1569-1574
19. Xu WD, Zhang M, Feng CC et al (2013) IL-32 with potential insights into rheumatoid arthritis. Clin Immunol 147(2):89-94
20. Heinhuis B, Koenders MI, Riel PL van et al (2011) Tumour necrosis factor alpha-driven IL-32 expression in rheumatoid arthritis synovial tissue amplifies an inflammatory cascade. Ann Rheum Dis 70(4):660-667
21. Moon YM, Yoon BY, Her YM et al (2012) IL-32 and IL-17 interact and have the potential to aggravate osteoclastogenesis in rheumatoid arthritis. Arthritis Res Ther 14(6):R246
22. Kwan BC, Tam LS, Lai KB et al (2009) The gene expression of type 17 T-helper cell-related cytokines in the urinary sediment of patients with systemic lupus erythematosus. Rheumatology (Oxford) 48(12):1491-1497
23. Yu Y, Liu Y, Shi FD et al (2013) Cutting edge: Leptin-induced RORγt expression in CD4+∈ T cells promotes Th17 responses in systemic lupus erythematosus. J Immunol 190(7):3054-3058
24. Hoffman C, Park SH, Daley E et al (2011) Interleukin-19: a constituent of the regulome that controls antigen presenting cells in the lungs and airway responses to microbial products. PLoS One 6(11):e27629
25. Yu X, Xia W, Zhang T et al (2010) Enhanced cytotoxicity of IL-24 gene-modified dendritic cells co-cultured with cytokine-induced killer cells to hepatocellular carcinoma cells. Int J Hematol 92(2):276-282
26. Horejs-Hoeck J, Schwarz H, Lamprecht S et al (2012) Dendritic cells activated by IFN-γ/STAT1 express IL-31 receptor and release proinflammatory mediators upon IL-31 treatment. J Immunol 188(11):5319-5326
27. Vigne S, Palmer G, Lamacchia C et al (2011) IL-36R ligands are potent regulators of dendritic and T cells. Blood 118(22):5813-5823
28. Rana A, Minz RW, Aggarwal R et al (2012) Gene expression of cytokines (TNF-α, IFN-γ), serum profiles of IL-17 and IL-23 in paediatric systemic lupus erythematosus. Lupus 21(10):1105-1112
29. Koenig KF, Groeschl I, Pesickova SS et al (2012) Serum cytokine profile in patients with active lupus nephritis. Cytokine 60(2):410-416
30. Song GG, Choi SJ, Ji JD, Lee YH (2013) Associations between interleukin-10 polymorphisms and susceptibility to systemic lupus erythematosus: a meta-analysis. Hum Immunol 74(3):364-370
31. Song GG, Choi SJ, Ji JD, Lee YH (2013) Association between interleukin-18 polymorphisms and systemic lupus erythematosus: a meta-analysis. Mol Biol Rep 40(3):2581-2587
32. Pan HF, Leng RX, Wang C et al (2012) Association of TNF-α promoter-308 A/G polymorphism with susceptibility to systemic lupus erythematosus: a meta-analysis. Rheumatol Int 32(7):2083-2092
33. Kyttaris VC, Kampagianni O, Tsokos GC (2013) Treatment with anti-interleukin 23 antibody ameliorates disease in lupus-prone mice. Biomed Res Int 2013:861028
34. Kyttaris VC, Zhang Z, Kuchroo VK et al (2010) Cutting edge: IL-23 receptor deficiency prevents the development of lupus nephritis in C57BL/6-lpr/lpr mice. J Immunol 184(9):4605-4609
35. Kahlenberg JM, Thacker SG, Berthier CC et al (2011) Inflammasome activation of IL-18 results in endothelial progenitor cell dysfunction in systemic lupus erythematosus. J Immunol 187(11):6143-6156